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microRNAsAbstract Radiotherapy is one of the most important methods for the treatment of breast cancer.
There is great interest in identifying factors that help to predict patient response to radiotherapy.
MicroRNAs (miRNAs) are a class of small RNA molecules that regulate gene expression at the
post-transcriptional level and play a key role in cellular responses to ionising radiation. Several reg-
ulatory proteins participate in breast tumour cell radiosensitivity and there are crosstalks between
miRNAs and these proteins at multiple levels. By analysing the relationships between miRNAs and
these proteins, we concluded that radioresistant and radiosensitive breast cancer patients might
have different patterns of some speciﬁc miRNAs. MiRNAs are present in body ﬂuids in a remark-
ably stable form and can easily be detected and quantiﬁed by quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR). It seems that proﬁling circulating miRNAs have the poten-
tial to be used for the prediction of radiotherapy outcome in breast cancer.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
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cause of cancer death in females worldwide. Annually, aboutersity of Medical Sciences, Ganjaf
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duces the efﬁciency of RT. Prediction of tumour response to
RT is highly beneﬁcial and minimises the risk of unnecessary
RT and subsequently its side effects. To date there is no robust
biomarker for identifying patients who do not respond to RT.
Identiﬁcation of the genes that are differentially expressed be-
tween radioresistant and radiosensitive BC patients could be a
method for predicting the response to RT. We provide evi-
dences that some special microRNAs (miRNAs) have different
expression in radioresistant and radiosensitive BC patients and
therefore have the potential to be used as a biomarker for pre-
dicting the response of BC patients to RT.
MiRNAs are a class of short, single-stranded and non-pro-
tein-coding RNA molecules that regulate gene expression via
degrading speciﬁc target messenger RNAs (mRNAs) or repress-
ing their translation.2 These molecules are implicated in several
cellular processes such as stress response, apoptosis, cellular dif-
ferentiation and proliferation and cellular response to ionising
radiation.3,4 MiRNAs have aberrant expression in a variety of
diseases including cancer. They are present in a remarkably sta-
ble form in the blood; in fact, circulating miRNAs are emerging
as important non-invasive biomarkers for cancer.5,6
Hypothesis
Although there are several prognostic risk factors for local
and systemic relapse of BC (patient’s age, race, tumor, node,
metastasis classiﬁcation (TNM) stage and histological sub-
type), a need for introducing reliable and robust markers
for prediction of patient response to different treatments
(especially response to RT) is growing. Several miRNAs are
involved in cellular response to ionising radiation.7 We
hypothesised that a number of miRNAs are important in
the resistance of breast tumour cells to RT and the proﬁles
of these miRNAs in radioresistant and radiosensitive BC pa-
tients are different. MiRNAs can be released into the blood
from normal or cancerous cells and are present in a remark-
ably stable form in the blood.8 If miRNA proﬁles in cancer-
ous cells of patients with different radiation sensitivity are not
the same, it is expected that their circulating proﬁle would be
also different. With consideration of this idea, it will be pos-
sible to predict the response of a patient to RT and determine
the personalised radiation dose by analysing these miRNAs
in the blood.
Evaluation of the hypothesis
For evaluation of this hypothesis, we should explain some re-
ported evidences:
(1) MiRNAs participate in the cellular response to ionising
radiation.
(2) Several proteins including vascular endothelial growth
factor (VEGF), epidermal growth factor receptor
(EGFR), human epidermal growth factor receptor-2
(Her-2/neu) and p53 are involved in breast tumour cells
radiosensitivity.9,10
(3) These proteins do parts of their regulatory roles by mod-
ulating the expression of some speciﬁc miRNAs. MiR-
NAs also participate in regulating the expression of
these proteins at the post-transcriptional level.(4) EGFR, Her-2/neu, VEGF, B-cell lymphoma 2 (BCL-2)
and p53 have different expressions in radioresistant and
radiosensitive BC patients.
In summary, we can see a close direct or inverse correlation
between miRNAs and the above-mentioned proteins in breast
tumour cells. As these proteins do not have the same expression
in radiosensitive and radioresistant BC patients, different
expression of their related miRNAs in these two groups of pa-
tients is not unexpected. Considering this point that miRNAs
are released into the blood and their circulating proﬁles change
in various diseases, we can test this hypothesis by analysing the
circulating levels of microRNAs in radioresistant and radiosen-
sitive BC patients using the quantitative real-time PCR (qRT-
PCR) method. Blood samples have to be collected before and
after the beginning of theRT. The relationship between circulat-
ing miRNA proﬁle and response to RT should be evaluated
after follow-up of patients. In the following, we will provide
more details about our hypothesis. In each section, we explain
the importance of a special protein in the radiosensitivity of
BC, its relatedmiRNAs and their roles inmodulating cellular re-
sponse to ionising radiation. At the end, wementionwhichmiR-
NAs have the most potential to be used as biomarkers for the
prediction of BC patients’ response to RT.
MiRNAs and HER-2/neu
HER-2/neu or ERBB-2 is a member of the ERBB family of
four receptor tyrosine kinases that form homodimers or het-
erodimers in response to a subset of growth factor ligands
and activate several pathways involved in cellular growth
and proliferation.11 About 30% of BC patients show overex-
pression of HER-2/neu in their tumour cells (HER-2/neu posi-
tive) that causes more aggressive behaviour of the tumour and
increased possibility of metastasis and resistance to RT.12–15
The use of an antibody against HER-2/neu (Herceptin) en-
hances radiation sensitivity in this group of patients.16 Cur-
rently, Herceptin is used as a drug for the treatment of BC
patients with excessive HER-2/neu.
Huang et al. explored the possibility that HER-2/neu sig-
nalling induces the expression of speciﬁc miRNAs involved
in the invasion and metastasis of BC cells.17 They found that
the expression of miR-21 is correlated with HER-2/neu up-reg-
ulation. miR-21 is up-regulated via the mitogen-activated pro-
tein kinase (MAPK) (extracellular signal-regulated kinase1/2,
ERK1/2) pathway upon stimulation of HER-2/neu signalling
in BC cells. Furthermore, the metastasis suppressor protein,
programmed cell death 4 (PDCD4) is down-regulated by
miR-21 in BC cells expressing HER2/neu. Thus, a mechanism
for HER2/neu-induced cancer cell invasion is via miR-21 and
overexpression of miR-21 can be expected in HER-2/neu-posi-
tive BC patients.
MiRNAs and EGFR
EGFR is another member of the ERBB family that is overex-
pressed in many tumours.18,19 Some anticancer drugs target
EGFR.20 Elevated EGFR is found in about 20% of BC
patients.21 A comprehensive study on 420 oestrogen recep-
tor-positive BC patients showed that blood EGFR level was
signiﬁcantly elevated, even 17 months prior to their cancer
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EGFR and the risk of developing BC in the near future.22
There is a direct correlation between EGFR level and resis-
tance to ionising radiation in breast tumour cells.23
Webster et al. in a study on several cancer cell lines (lung,
breast, and glioblastoma) found that miR-7 down-regulates
EGFR mRNA and protein expression via two sites on the
30-untranslated region of EGFR mRNA, inducing cell cycle ar-
rest and cell death.24 Furthermore in another study researchers
showed that ectopic overexpression of miR-7 attenuated
EGFR and protein kinase B (Akt) expression and radiosensi-
tised MDA-MB-468 BC cells.25 Thus, we can conclude from
these two studies that there is an inverse correlation between
EGFR and miR-7 level in breast tumour cells. Chen et al. re-
ported that EGFR up-regulates miR-206 level and miR-206
down-regulates the oestrogen receptor alpha (ERa) mRNA.
As there is excessive EGFR in ERa-negative BC patients, the
authors proposed that EGFR-induced miR-206 attenuated
ERa gene expression.
26 From the above discussion, a decrease
in miR-7 level and an increase in miR-206 level are expected in
BC patients who have excessive EGFR and so are
radioresistant.
MiRNAs and VEGF
VEGF is an angiogenic factor that stimulates the growth and
proliferation of endothelial cells. The expression of VEGF in-Figure 1 A simpliﬁed working model that shows correlation between
cells. Orange colors show miRNAs and proteins that are expected to u
and factors that are expected to downregulate in radioresistant BC p
ERa: estrogen receptor alpha, BCL-2: B-cell lymphoma 2, HER-2: Hu
cell death 4, MDM2: murine double minute 2, AKT: Protein Ki
Phosphatase and tensin homolog, ERK: extracellular signal-regulate
vascular endothelial growth factor. The numbers in brackets are related
in this ﬁgure legend, the reader is referred to the web version of this acreases under hypoxic conditions and stimulates angiogene-
sis.27 Anti-angiogenic drugs increase radiosensitivity.28
Linderholm et al. showed that the VEGF level in BC patients
who do not respond to RT is signiﬁcantly higher than other
BC patients and there is an inverse correlation between VEGF
level and relapse-free survival and overall survival.29 Thus, we
can consider VEGF to be an important factor for resistance to
RT in BC patients.28
Several miRNAs are involved in the regulation of the
angiogenic process. Expression of miR-21 up-regulates VEGF
and ERK1/2 genes by down-regulating phosphatase and tensin
homolog (PTEN) mRNA.30 Hafez et al. showed that in breast
tumour tissues having increased miR-21, the expression level
of VEGF was up-regulated. They showed that miR-15 and
miR-16 also regulate VEGF expression. These two miRNAs
down-regulate under the hypoxic condition that is observed
in tumours resistant to ionising radiation. VEGF up-regulates
miR-191, -155, -31, -17, -18a and -20a in human endothelial
cells.31 All these miRNAs are overexpressed in human tumours
and participate in the control of tumour growth, survival and
angiogenesis.32
MiRNAs and BCL-2
BCL-2 is an important antiapoptotic protein associated with
cancer.33 This protein is overexpressed in nearly 70% of BC
patients.34–36 Cells that overexpress this molecule aremiRNAs and proteins involved in radioresistancy of breast tumor
pregulate in radioresistant BC patients. Blue colors show miRNAs
atients. Abbreviations: EGFR: epidermal growth factor receptor,
man Epidermal Growth Factor Receptor 2, PDCD4: programmed
nase B or PKB, PI3K: Phosphatidylinositol 3-kinases, PTEN:
d kinase or Mitogen-activated protein kinase (MAPK), VEGF:
to the cited articles. (For interpretation of the references to colour
rticle.)
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BC patients gain more beneﬁt from RT than BCL-2-positive
patients and RT causes a 6-fold reduction of recurrence in
these patients. These tumours show features favouring apopto-
sis because of decreased Bcl-2 expression and thus are more
sensitive to ionising radiation.38
Several miRNAs are important in regulating Bcl-2 expres-
sion. miR-15 and miR-16 in chronic lymphocytic leukaemia
(CLL), miR-29 in hepatocellular carcinoma and miR-148a in
colorectal cancer induce apoptosis by targeting Bcl-2.39,40
Zhu et al. showed miR-21 overexpression in breast tumours
compared to the matched normal breast tissues (among 157
human miRNAs) and suggested that miR-21 may regulate
BCL-2 expression indirectly.41
MiRNAs and P53
p53 is a tumour suppressor gene that inhibits cancer cell
growth and proliferation by regulating several pathways.42
Mutations of the p53 gene occur in about 50% and dysfunc-
tional p53 signalling occurs in about 80% of all human can-
cers.43,44 There is a direct correlation between p53 mutation
and resistance of breast tumour cells to ionising radiation
due to abnormal p53-depenent apoptosis.45 Node-negative
BC patients with increased p53 protein levels are more radio-
sensitive and gain more beneﬁt from postoperative RT com-
pared to patients with wild-type p53.46 Amornman et al. in a
study for determining risk factors of local recurrence and
metastasis in BC after lumpectomy with postoperative RT
found that the expression of p53 was associated with all local
recurrence cases and 50% of metastatic patients.47
There are several crosstalks between p53 and miRNAs at
multiple levels.48 p53 promotes the post-transcriptional matu-
ration of a number of miRNAs including miR-16-1, miR-143
and miR-145 and also induces the transcription expression of
some others including miR-145, miR-107, miR-192 and miR-
215. Meanwhile, some miRNAs such as miR-504 and miR-
125b directly down-regulate p53. In breast tumour cells, miR-
29 indirectly up-regulates p53 protein levels by repression of
some speciﬁc factors. In addition, p53 directly induces the tran-
scriptional expression of miR-34a.48,49 Ionising radiation in-
duces expression of miR-34a in a p53-dependent manner and
Bcl-2 is one of the possible downstream targets of miR-34a.50
Conclusion
A big obstacle for the treatment of BC is that some patients do
not respond to RT. Prediction of the RT response helps to pre-
vent overtreatment or undertreatment. In this hypothesis,
authors have attempted to propose a biomarker for prediction
of response to RT in BC. We drew Fig. 1 according to the
above discussion. Considering this ﬁgure it is obvious that
miR-21 and miR-206 are up-regulated and miR-7, -34a, -29,
-15 and -16 are down-regulated in radioresistant BC patients.
All of these miRNAs have been detected in the blood of nor-
mal or BC patients in previous studies.51–55 Therefore, it may
be possible to use these miRNAs’ proﬁles in the blood for pre-
diction of patients’ response to RT. This can be very advanta-
geous because of the high stability and easy quantiﬁcation of
miRNAs using qRT-PCR.Overview Box
What do we already know about the subject?
1. Breast cancer is the leading cause of cancer death in
females.
2. Radiotherapy is widely used for the treatment of
breast cancer.
3. Some breast cancer patients are resistant to radio-
therapy and there is no robust biomarker for distin-
guishing this group of patients.
4. Several proteins are involved in resistance of breast
tumour cells to ionising radiation.
5. There are crosstalks between microRNAs and these
proteins at multiple levels.
What does your proposed theory add to the current
knowledge available, and what beneﬁt does it have?
We provide evidences that some miRNAs including
miR-21, -206, -7, -34a, -29, -15 and -16 have altered
expressions in breast cancer patients resistant to radio-
therapy. This hypothesis introduces miRNAs as new
biomarkers for prediction of breast cancer patients’
response to radiotherapy.
Among numerous available studies, what special further
study is proposed for testing the idea?
This hypothesis can easily be tested by analysing circu-
lating levels of microRNAs in radioresistant versus
radiosensitive breast cancer patients using qRT-PCR.
Blood samples have to be collected in two phases: ﬁrst
before beginning of the radiotherapy and then after
end of the radiotherapy; and serum or plasma stored
at 80 C. Circulating levels of miRNAs in these
patients have to be analysed after follow-up of patients
and observing their response to radiotherapy.References
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